Related Experiment Video
Updated: Jan 4, 2026
Multiplexed Immunofluorescence Analysis and Quantification of Intratumoral PD-1+ Tim-3+ CD8+ T Cells
Published on: February 8, 2018
Factors Influencing the Efficacy of Anti-PD-1 Therapy in Chinese Patients with Advanced Melanoma
Lingdi Zhao1, Yonghao Yang1, Baozhen Ma1
1Department of Immunotherapy, Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou City, Henan Province, China.
Purpose:
Anti-PD-1 antibody improves the survival of patients with advanced melanoma. However, the efficacy and safety of anti-programmed death protein 1 (PD-1) antibody have not been fully elucidated in Chinese melanoma patients, who show high frequency of mucosal and acral melanoma subtypes; besides, the factors influencing the efficacy of anti-PD-1 antibody have not been evaluated broadly.
Patients And Methods:
Patients with advanced melanoma treated with regimens containing anti-PD-1 antibody from June 2016 to January 2019 were evaluated. Baseline characteristics and blood parameters were assessed, and outcome and adverse events were evaluated according to different regimens. The Cox proportional hazards regression model was used for univariate and multivariate analyses.
Results:
A total of 51 patients with advanced melanoma were included in this study. The overall objective response rate (ORR) was 17.6%, the disease control rate was 58.5%, and the median time to progression was 5.2 months. The ORR of patients with PD-1 blockade-based combination therapy, without liver metastases and higher level of C-reactive protein (CRP) before PD-1 blockade, is higher than that of those not. Univariate analysis based on clinical features showed that ECOG scores, liver metastasis, elevated lactate dehydrogenase (LDH), and CRP levels were the factors affecting time to progression (TTP). Multivariate analysis showed that elevated CRP before PD-1 blockade was an independent predictive factor for ORR of PD-1 blockade therapy (P=0.009), while only Eastern Cooperative Oncology Group (ECOG) score was an independent predictor for TTP (P=0.032). The treatment was well tolerated in these cohort patients, and there was no treatment-related death.
Conclusion:
Anti-PD-1 antibody-containing regimen was safe and effective in Chinese patients with advanced melanoma, and elevated CRP and ECOG score were independent factors predicting the efficacy of anti-PD-1 therapy.
Insights
Anti-programmed death protein 1 (PD-1) antibody therapy is safe and effective for advanced melanoma in Chinese patients. Elevated C-reactive protein (CRP) and Eastern Cooperative Oncology Group (ECOG) scores predict treatment efficacy.
Area of Science:
- Oncology
- Immunotherapy
- Melanoma Research
Background:
- Anti-programmed death protein 1 (PD-1) antibody therapy has shown promise in improving survival for advanced melanoma patients.
- The efficacy and safety of anti-PD-1 antibody therapy in Chinese melanoma patients, who have a higher incidence of mucosal and acral subtypes, require further elucidation.
- Factors influencing the efficacy of anti-PD-1 antibody therapy in this population have not been extensively evaluated.
Purpose of the Study:
- To evaluate the efficacy and safety of anti-PD-1 antibody-containing regimens in Chinese patients with advanced melanoma.
- To identify clinical and blood parameters that influence the outcomes of anti-PD-1 antibody therapy in this cohort.
- To explore predictive factors for response and progression-free survival in advanced melanoma patients treated with anti-PD-1 antibodies.
Main Methods:
- Retrospective evaluation of 51 advanced melanoma patients treated with anti-PD-1 antibody regimens from June 2016 to January 2019.
- Assessment of baseline characteristics, blood parameters, treatment outcomes (objective response rate, disease control rate), and adverse events.
- Application of Cox proportional hazards regression for univariate and multivariate analyses to identify predictive factors.
Main Results:
- The overall objective response rate (ORR) was 17.6%, with a disease control rate of 58.5% and a median time to progression of 5.2 months.
- Higher ORR was observed in patients receiving combination therapy, without liver metastases, and with higher baseline C-reactive protein (CRP) levels.
- Multivariate analysis identified elevated CRP as an independent predictor for ORR (P=0.009) and Eastern Cooperative Oncology Group (ECOG) score for time to progression (P=0.032).
Conclusions:
- Anti-PD-1 antibody-containing regimens demonstrate safety and efficacy in Chinese patients with advanced melanoma.
- Elevated CRP levels and ECOG scores are identified as independent factors predicting the efficacy of anti-PD-1 therapy.
- The findings provide valuable insights into optimizing anti-PD-1 therapy for advanced melanoma in the Chinese population.
